Back to Agenda
[V1-S4] What Roles should MA Division be in Charge of? - To Be the Bridge between Development and Academia as Well as Clinical Practice
Session Chair(s)
Kazuya Iwamoto, MD, PHD, FACP
Chairperson, The Japanese Association of Pharmaceutical Medicine (JAPhMed), Senior Medical Director, Covance Inc., Japan
Recently, more and more pharmaceutical companies have been establishing Medical Affairs (MA) departments in Japan. MA plays important roles in optimizing value of products from medical/scientific perspective and in bridging between Development and Academia as well as Clinical Practice, having various responsibilities including Medical Information/Communication, engaging with Key Opinion Leaders, dealing with Investigator Sponsored Studies and reviewing promotional materials. Medical Science Liaison (MSL) plays a critical role in bridging between them and is being increasingly recognized by medical personnel and the pharmaceutical industry. This session will feature expert lectures on the roles/responsibilities required for MA and the current MA activities, followed by discussions on what roles MA should be in charge of in Japan.
Speaker(s)
Kazuya Iwamoto, MD, PHD, FACP
Chairperson, The Japanese Association of Pharmaceutical Medicine (JAPhMed), Senior Medical Director, Covance Inc., Japan
The Core Role of MA
Yasushi Matsuo
Vice President of Medical, AstraZeneca K.K., Japan
MSL Certification Accreditation
Antonio Martin, MD, PHD, MSC
Corporate Officer, Head Medical Division, Novartis Pharma K.K., Japan
What Pharmaceutical Companies Expect of, and How They Support Investigator Initiated Trials (IIT)
Makoto Shiragami, PHD
Professor, Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Japan
Issues with Provision of Prescription Drug Information
Have an account?